Carbohydrate polymersAnimalsChondroitin SulfatesMiceParkinson DiseaseMale
Oral efficacy of structurally defined chondroitin sulfate Co-administered with SNAC in Parkinson's disease.
Ying Guo, Bin Zhang, Changkai Bu, Zizhe An, Deling Shi, Lan Jin, Anran Sheng, Aihua Zhen, Lianli Chi
Published: 202610.1016/j.carbpol.2025.124492
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder with limited therapeutic options and suboptimal long-term efficacy. Although glycosaminoglycans such as chondroitin sulfate (CS) possess neuroprotective potential, their clinical ap…
Preview only. Read the full abstract at the source